CRYOPORT, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
CRYOPORT, INC. (CYRX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $300.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2021-11-04
- 2021-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $300.00K.
- 2021-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $300.00K.
- 2021-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $300.00K.
- 2020-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $300.00K; Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed $279.40K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2021-09-30 | $300.00K 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $300.00K 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $300.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $300.00K 10-Q · filed 2021-11-04 | $279.40K 10-K · filed 2021-03-01 |
| 2020-09-30 | $273.70K 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $269.40K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $273.70K 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $71.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $71.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $71.10K 10-Q · filed 2019-08-09 | |
| 2018-12-31 | $71.00K 10-K · filed 2020-03-10 | $71.10K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |